The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 04, 2016
Filed:
Jul. 08, 2014
Applicant:
Orexigen Therapeutics, Inc., La Jolla, CA (US);
Inventors:
Michael A. Cowley, Portland, OR (US);
Anthony A. McKinney, San Diego, CA (US);
Gary Tollefson, Indianapolis, IN (US);
Assignee:
OREXIGEN THERAPEUTICS, INC., San Diego, CA (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/28 (2006.01); A61K 31/135 (2006.01); A61K 31/485 (2006.01); A61K 31/5513 (2006.01); A61K 31/35 (2006.01); A61K 31/4525 (2006.01); A61K 31/423 (2006.01); A61K 31/55 (2006.01); A61K 31/138 (2006.01); A61K 31/445 (2006.01); A61K 31/519 (2006.01); A61K 31/5415 (2006.01); A61K 31/551 (2006.01); A61K 31/554 (2006.01); A61K 31/7048 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/35 (2013.01); A61K 31/135 (2013.01); A61K 31/138 (2013.01); A61K 31/423 (2013.01); A61K 31/445 (2013.01); A61K 31/4525 (2013.01); A61K 31/485 (2013.01); A61K 31/519 (2013.01); A61K 31/5415 (2013.01); A61K 31/55 (2013.01); A61K 31/551 (2013.01); A61K 31/554 (2013.01); A61K 31/5513 (2013.01); A61K 31/7048 (2013.01); A61K 38/28 (2013.01); A61K 45/06 (2013.01);
Abstract
Methods and compositions for treating a blood glucose condition involve identifying a suitable subject and administering an effective amount of a composition that contains one or more of an opioid antagonist, an anticonvulsant, and a psychotherapeutic agent. The compositions can include insulin. In some embodiments, such methods and compositions can be used to modulate a blood glucose level. In preferred embodiments, such methods and compositions are useful for increasing a subject's sensitivity to insulin.